Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1978 Aug;75(8):4006–4010. doi: 10.1073/pnas.75.8.4006

Specific immunosuppression of experimental autoimmune myasthenia gravis by denatured acetylcholine receptor.

D Bartfeld, S Fuchs
PMCID: PMC392919  PMID: 279016

Abstract

Specific immunosuppression of experimental autoimmune myasthenia gravis (EAMG) was achieved by the use of a denatured preparation of the acetylcholine receptor (AcChoR) that did not in itself induce the disease. Torpedo californica AcChoR was irreversibly denatured by complete reduction and carboxymethylation in 6 M guanidine hydrochloride. Rabbits immunized with reduced carboxymethylated receptor (RCM-AcChoR) produced antibodies that reacted with both RCM-AcChoR and intact AcChoR. The specificity of anti-RCM-AcChoR antibodies is different from that of anti-AcChoR antibodies because the former are directed to only part of the antigenic determinants present in the intact receptor. RCM-AcChoR, which by itself is completely nonmyasthenic, was shown to be capable of both preventing the onset of EAMG and of reversing the clinical symptoms in myasthenic rabbits. In all cases the therapeutic effect of RCM-AcChoR administration on EAMG was accompanied by a change in the immunological specificity of the antibodies. The crossreactivity between AcChoR and RCM-AcChoR and the nonpathogenicity of RCM-AcChoR appear to be crucial in governing the specific immunosuppressive effects of RCM-AcChoR on EAMG.

Full text

PDF
4006

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abramsky O., Aharonov A., Teitelbaum D., Fuchs S. Myasthenia gravis and acetylcholine receptor. Effect of steroids in clinical course and cellular immune response to acetylcholine receptor. Arch Neurol. 1975 Oct;32(10):684–687. doi: 10.1001/archneur.1975.00490520054008. [DOI] [PubMed] [Google Scholar]
  2. Abramsky O., Aharonov A., Webb C., Fuchs S. Cellular immune response to acetylcholine receptor-rich fraction, in patients with myasthenia gravis. Clin Exp Immunol. 1975 Jan;19(1):11–16. [PMC free article] [PubMed] [Google Scholar]
  3. Abramsky O., Tarrab-Hazdai R., Aharonov A., Fuchs S. Immunosuppression of experimental autoimmune myasthenia gravis by hydrocortisone and azathioprine. J Immunol. 1976 Jul;117(1):225–228. [PubMed] [Google Scholar]
  4. Aharonov A., Abramsky O., Tarrab-Hazdai R., Fuchs S. Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis. Lancet. 1975 Aug 23;2(7930):340–342. doi: 10.1016/s0140-6736(75)92779-8. [DOI] [PubMed] [Google Scholar]
  5. Aharonov A., Tarrab-Hazdai R., Silman I., Fuchs S. Immunochemical studies on acetylcholine receptor from Torpedo californica. Immunochemistry. 1977 Feb;14(2):129–137. doi: 10.1016/0019-2791(77)90291-9. [DOI] [PubMed] [Google Scholar]
  6. Appel S. H., Almon R. R., Levy N. Acetylcholine receptor antibodies in myasthenia gravis. N Engl J Med. 1975 Oct 9;293(15):760–761. doi: 10.1056/NEJM197510092931508. [DOI] [PubMed] [Google Scholar]
  7. Bartfeld D., Fuchs S. Immunological characterization of an irreversibly denatured acetylcholine receptor. FEBS Lett. 1977 May 15;77(2):214–218. doi: 10.1016/0014-5793(77)80237-8. [DOI] [PubMed] [Google Scholar]
  8. Clark D. G., Macmurchie D. D., Elliott E., Wolcott R. G., Landel A. M., Raftery M. A. Elapid neurotoxins. Purification, characterization, and immunochemical studies of -bungarotoxin. Biochemistry. 1972 Apr 25;11(9):1663–1668. doi: 10.1021/bi00759a020. [DOI] [PubMed] [Google Scholar]
  9. Genkins G., Kornfeld P., Osserman K. E., Namba T., Grob D., Brunner N. G. The use of ACTH and corticosteroids in myasthenia gravis. Ann N Y Acad Sci. 1971 Sep 15;183:369–374. doi: 10.1111/j.1749-6632.1971.tb30766.x. [DOI] [PubMed] [Google Scholar]
  10. Lindstrom J. M., Lennon V. A., Seybold M. E., Whittingham S. Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects. Ann N Y Acad Sci. 1976;274:254–274. doi: 10.1111/j.1749-6632.1976.tb47691.x. [DOI] [PubMed] [Google Scholar]
  11. Matell G., Bergström K., Franksson C., Hammarström L., Lefvert A. K., Möller E., von Reis G., Smith E. Effects of some immunosuppressive procedures on myasthenia gravis. Ann N Y Acad Sci. 1976;274:659–676. doi: 10.1111/j.1749-6632.1976.tb47724.x. [DOI] [PubMed] [Google Scholar]
  12. Seybold M. E., Drachman D. B. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med. 1974 Jan 10;290(2):81–84. doi: 10.1056/NEJM197401102900204. [DOI] [PubMed] [Google Scholar]
  13. Tarrab-Hazdai R., Abramsky O., Fuchs S. Immunosuppression of experimental autoimmune myasthenia gravis by azathioprine. II. Evaluation of immunological mechanism. J Immunol. 1977 Aug;119(2):702–706. [PubMed] [Google Scholar]
  14. Valderrama R., Weill C. L., McNamee M., Karlin A. Isolation and properties of acetylcholine receptors from Electrophorus and Torpedo. Ann N Y Acad Sci. 1976;274:108–115. doi: 10.1111/j.1749-6632.1976.tb47679.x. [DOI] [PubMed] [Google Scholar]
  15. Warmolts J. R., Engel W. K. Benefit from alternate-day prednisone in myasthenia gravis. N Engl J Med. 1972 Jan 6;286(1):17–20. doi: 10.1056/NEJM197201062860104. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES